EMD Millipore, Sysmex Collaborate on Flow Cytometry Technology Platform | GenomeWeb

NEW YORK (GenomeWeb News) – EMD Millipore today announced a clinical research, licensing, and joint development deal with Japan's Sysmex aimed at creating a flow cytometry platform for blood disorders.

The companies will use EMD Millipore's flow cytometry technology as a platform to accelerate the development of new diagnostic tools. If successful, they will then develop the platform for commercialization in the hematology space, EMD Millipore, division of Germany's Merck KGaA, said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.